Skip to main content
A

Ananda Pharma Plc — Investor Relations & Filings

Ticker · ANAN ISIN · GB00BDQPXQ60 LEI · 894500DFM8VOC5FW4X47 Aquis Stock Exchange Manufacturing
Open in API
Filings indexed 196 across all filing types
Latest filing 2025-07-30 AGM Information
Country GB United Kingdom
Listing Aquis Stock Exchange ANAN

About Ananda Pharma Plc

https://www.anandapharma.co.uk/

Ananda Pharma Plc is a biopharmaceutical company focused on the development of regulatory-approved, cannabinoid-based medicines. The company's primary mission is to create therapies for complex, chronic inflammatory conditions with significant unmet medical needs. Its development pipeline is initially centered on treatments for inflammatory pain conditions, including Chemotherapy-Induced Peripheral Neuropathy (CIPN) and endometriosis, as well as heart failure with preserved ejection fraction (HFpEF). Ananda Pharma's approach covers the full development cycle, from identifying clinical potential and optimizing drug candidates to conducting clinical trials and securing marketing authorizations from regulators.

Recent filings

Filing Released Lang Actions
Notice of Annual General Meeting
AGM Information Classification · 98% confidence The document is an announcement from Ananda Pharma PLC regarding the distribution of the Notice of Annual General Meeting to shareholders. It provides the date, time, and location of the upcoming AGM and directs shareholders to a website link to access the full meeting materials. Per the 'Menu vs Meal' rule, this is an announcement about a report/notice rather than the notice itself, and it fits the definition of a Report Publication Announcement (RPA).
2025-07-30 English
Publication of Annual Report
Audit Report / Information Classification · 95% confidence The document is an RNS (Regulatory News Service) announcement from Ananda Pharma PLC. It explicitly states 'Publication of Annual Report' and provides a link to the full report on the company's website. According to the 'Menu vs Meal' rule, since this is a short announcement (under 5,000 characters of actual content, excluding the boilerplate) that directs the reader to an external link for the full report, it is classified as a Report Publication Announcement (RPA). FY 2025
2025-07-30 English
First Participant Dosed in MRX1 CBD Phase 1 Study
Regulatory Filings Classification · 100% confidence The document is a press release issued via the Regulatory News Service (RNS) regarding a clinical trial milestone (first participant dosed in a Phase 1 study). It contains inside information as defined by UK MAR. Since it is a general regulatory announcement regarding company operations and clinical progress that does not fit into specific categories like financial reports, dividends, or board changes, it is classified as a Regulatory Filing (RNS).
2025-07-15 English
MRX1 Delivered to Clinical Trial Site
Regulatory Filings Classification · 100% confidence The document is a regulatory announcement issued via the London Stock Exchange's RNS (Regulatory News Service). It details a specific operational milestone for Ananda Pharma PLC, namely the delivery of an investigational product (MRX1) to a clinical trial site. As this is a general corporate announcement regarding business operations and clinical progress that does not fit into specific categories like financial reports, dividends, or M&A, it is classified as a Regulatory Filing (RNS).
2025-07-01 English
Key Milestone in MRX1 Path to Clinical Trials
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 8561N' and is dated June 23, 2025. It contains standard regulatory boilerplate language regarding 'INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU' and concludes with information about RNS being the news service of the London Stock Exchange, which is characteristic of a regulatory news service announcement. The content itself details a key operational milestone (manufacturing of clinical-grade batches of MRX1) and is not a full financial report (like 10-K or IR), a formal proxy statement (DEF 14A), or a transcript (CT). Since it is a general, material, non-financial announcement disseminated via the RNS system, it fits best under the general Regulatory Filings category (RNS), as it is not specifically covered by other codes like DIRS, DIV, or CAP. The document length is moderate (7359 chars), but the structure is clearly that of an RNS announcement.
2025-06-23 English
Publication of Phase 1 study on clinicaltrials.gov
Regulatory Filings Classification · 98% confidence The document is a press release distributed via the London Stock Exchange's 'Reach' service. It announces the publication of a Phase 1 clinical study on clinicaltrials.gov. Since it is a corporate announcement regarding company news (clinical trial progress) that does not fit into specific financial reporting categories like 10-K, IR, or ER, and is not a report itself but an announcement of external information, it falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2025-06-03 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.